Advertisement

Vulvovaginal Candidiasis in Pregnancy

  • T. J. Aguin
  • J. D. SobelEmail author
Genitourinary Infections (J Sobel, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Genitourinary Infections

Abstract

Prevalence studies indicate that Candida species colonize the vagina in at least 20 % of all women, rising to 30 % in pregnancy. Although, some studies concluded that pregnant women were more likely to have symptomatic vaginal infections caused by Candida, yet other studies found a high prevalence of asymptomatic infection only during pregnancy. Most episodes of symptomatic vulvovaginal candidiasis (VVC) occur during the second and third trimesters. The increased risk of VVC in pregnancy is likely sustained by pregnancy-related factors, such as immunologic alterations, increased estrogen levels, and increased vaginal glycogen production. Although evidence is incomplete, there is some emerging data which suggests that candidiasis in pregnancy may be associated with increased risk of pregnancy complications, such as premature rupture of membranes, preterm labor, chorioamnionitis, and congenital cutaneous candidiasis. In contrast to nonpregnant women, there are no formal studies, evaluating the use of long-term suppressive maintenance oral azoles in the treatment of recurrent VVC (RVVC) in pregnancy. Most clinicians do not offer suppressive therapy in pregnancy and prefer to treat individual symptomatic episodes only utilizing a topical imidazole vaginally for 7 days to minimize systemic exposure to medications.

Keywords

Vulvovaginal Candidiasis Recurrent Pregnancy 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Tina Aguin and Jack Dr Sobel have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Jaeger M, Plantinga TS, Joosten LA, Kullberg B, Netea M. Genetic basis for recurrent vulvo-vaginal candidiasis. Curr Infect Dis Rep. 2013;15:136–42.CrossRefPubMedGoogle Scholar
  2. 2.
    Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369:1961–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Mendling W, Brasch J. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. Mycoses. 2012;55:1–13.CrossRefPubMedGoogle Scholar
  4. 4.
    Fardiazar Z, Ronaci F, Torab R, Goldust M. Vulvovaginal candidiasis recurrence during pregnancy. Pak J Biol Sci. 2012;15:399–402.CrossRefPubMedGoogle Scholar
  5. 5.
    Galask RP. Vaginal colonization by bacteria and yeast. Am J Obstet Gynecol. 1988;158:993–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Akerele J, Abhulimen P, Okonofua F. Prevalence of asymptomatic genital infection among pregnant women in Benin City, Nigeria. Afr J Reprod Health. 2002;6:93–7.CrossRefPubMedGoogle Scholar
  7. 7.
    de Oliveira JM, Cruz AS, Fonseca AF, Vaz CP, Rodrigues A, Aurea F, et al. Prevalence of Candida albicans in vaginal fluid of asymptomatic Portuguese women. J Reprod Med. 1993;38:41–2.PubMedGoogle Scholar
  8. 8.•
    Leli C, Mencacci A, Meucci M, Bietolini C, Vitalli M, Farinelli S, et al. Association of pregnancy and Candida vaginal colonization in women with or without symptoms of vulvovaginitis. Minerva Ginecol. 2013;65:303–9. This study found that pregnancy is independently associated with a lower probability of having symptoms of Candida vulvovaginitis. The possible explanation is the modulation of maternal immune system and the anti-inflammatory state present during pregnancy. PubMedGoogle Scholar
  9. 9.
    Nelson DB, Bellamy S, Nachamkin I, Ruffin A, Allen-Taylor L, Friedenberg FK. Characteristics and pregnancy outcomes of pregnant women asymptomatic for bacterial vaginosis. Matern Child Health J. 2008;12:216–22.CrossRefPubMedGoogle Scholar
  10. 10.
    Sobel JD. Genital candidiasis. In: Bodey GP, editor. Candidiasis: pathogenesis, diagnosis and treatment. 2nd ed. New York, NY: Raven; 1993. p. 225–47.Google Scholar
  11. 11.
    Ilkit M, Guzel AB. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective. Crit Rev Microbiol. 2011;37:250–61.CrossRefPubMedGoogle Scholar
  12. 12.•
    Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. N Engl J Med. 2014;370:2211–8. This article discusses evolving concepts of immunologic alterations during pregnancy that may help explain the altered severity of and susceptibility of infectious diseases in pregnancy. CrossRefPubMedGoogle Scholar
  13. 13.
    Cvoro A, Tatomer D, Tee MK, Zogovic T, Harris HA, Leitman DC. Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol. 2008;180:L630–6.CrossRefGoogle Scholar
  14. 14.
    Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28:521–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Robinson DP, Klein SL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm Behav. 2012;62:263–71.CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Szekeres-Bartho J, Wegmann TG. A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. J Reprod Immunol. 1996;31:81–95.CrossRefPubMedGoogle Scholar
  17. 17.
    Mor G, Cardenas I. The immune system in pregnancy: a unique complexity. Am J Reprod Immunol. 2010;62:425–33.CrossRefGoogle Scholar
  18. 18.
    Pazos M, Sperling RS, Moran TM, Kraus TA. The influence of pregnancy on systemic immunity. Immunol Res. 2012;54:254–61.CrossRefPubMedGoogle Scholar
  19. 19.
    Kraus TA, Engel SM, Sperling RS, Kellerman L, Lo Y, Wallenstein S, et al. Characterizing the pregnancy immune phenotype: results of the Viral Immunity and Pregnancy (VIP) study. J Clin Immunol. 2012;32.Google Scholar
  20. 20.
    Zoller AL, Schnell FJ, Kersh GJ. Murine pregnancy leads to reduced proliferation of maternal thymocytes and decreased thymic emigration. Immunology. 2007;121:207–15.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Clarke AG, Kendall MD. The thymus in pregnancy: the interplay of neural, endocrine and immune influences. Immunol Today. 1994;15:545–51.CrossRefPubMedGoogle Scholar
  22. 22.
    Forbes RL, Gibson PG, Murphy VE, Wark PAB. Impaired type I and III interferon response to rhinovirus infection during pregnancy and asthma. Thorax. 2012;67:209–14.CrossRefPubMedGoogle Scholar
  23. 23.
    Medawar P. Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. Symp Soc Exp Biol. 1953;7:320–38.Google Scholar
  24. 24.
    Lissauer D, Piper K, Goodyear O, Kilby MD, Moss PA. Fetal-specific CD8+ cytotoxic T cell responses develop during normal human pregnancy and exhibit broad functional capacity. J Immunol. 2012;189:1072–80.CrossRefPubMedGoogle Scholar
  25. 25.
    Sperling RS, Engel SM, Wallenstein S, Kraus TA, Garrido J, Singh T, et al. Immunogenicity of trivalent inactivated influenza vaccination received during pregnancy or postpartum. Obstet Gynecol. 2012;119:631–9.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Ohfuji S, Fukushima W, Deguchi M, Kawabata K, Yoshida H, Hatayama H, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine among pregnant women: lowered antibody response by prior seasonal vaccination. J Infect Dis. 2011;203:1301–8.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Healy CM. Vaccines in pregnant women and research initiatives. Clin Obstet Gynecol. 2012;55:474–86.CrossRefPubMedGoogle Scholar
  28. 28.
    Munoz FM, Bond NH, Maccato M, Pinell P, Hammill HA, Swamy GK, et al. Safety and immunogenicity of Tdap vaccine in healthy pregnant women, safety in their neonates, and effect of maternal immunization on infant immune responses to DTaP vaccine. Presented at the 2nd International Maternal Neonatal Immunization Symposium, Antalya, Turkey, March 1–3, 2013. abstract.Google Scholar
  29. 29.
    Carvalho LP, Bacellar O, Neves N, de Jesus AR, Carvalho EM. Downregulation of IFN-gamma production in patients with recurrent vaginal candidiasis. J Allergy Clin Immunol. 2002;109:102–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Dekel N, Gnainsky Y, Granot I, Mor G. Inflammation and implantation. Am J Reprod Immunol. 2010;63:17–21.CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    Mor G. Inflammation and pregnancy: the role of toll-like receptors in trophoblast-immune interaction. Ann N Y Acad Sci. 2008;1127:121–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Mazor M, Chaim W, Shinwell ES, Glezerman M. Asymptomatic amniotic fluid invasion with Candida albicans in preterm premature rupture of membranes. Implications for obstetric and neonatal management. Acta Obstet Gynecol Scand. 1993;72:52–4.CrossRefPubMedGoogle Scholar
  33. 33.•
    Roberts CL, Rickard K, Kotsiou G, Morris JM. Treatment of asymptomatic vaginal candidiasis in pregnancy to prevent preterm birth: an open label pilot randomized controlled trial. BMC Pregnancy Childbirth. 2011;11:18. This pilot study demonstrated a tendency towards a reduction in spontaneous preterm birth among women with asymptomatic candidiasis who were treated with clotrimazole. CrossRefPubMedCentralPubMedGoogle Scholar
  34. 34.
    Meizoso T, Rivera T, Fernandez-Acenero MJ. Intrauterine candidiasis: report of four cases. Arch Gynecol Obstet. 2008;278:173–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Friebe-Hoffman U, Bender D, Sims C, Rauk P. Candida albicans chorioamnionitis associated with preterm labor and sudden intrauterine demise of one twin, a case report. J Reprod Med. 2000;45:354–6.Google Scholar
  36. 36.
    Chaim W, Mazor M, Wiznitzer A. The prevalence and clinical significance of intraamniotic infection with Candida species in women with preterm labor. Arch Gynecol Obstet. 1992;251:9–15.CrossRefPubMedGoogle Scholar
  37. 37.
    Bean LM, Jackson JR, Dobak WJ, Beiswenger TR, Thorp JA. Intra-amniotic fluconazole therapy for Candida albicans intra-amniotic infection. Obstet Gynecol. 2013;121:452–4.PubMedGoogle Scholar
  38. 38.
    Sfamemi SF, Talbot JM, Chow SL, Brenton LA, Scurry JP. Candida glabrata chorioamnionitis following in vitro fertilization and embryo transfer. Aust NZ J Obstet Gynaecol. 1997;37:88–91.CrossRefGoogle Scholar
  39. 39.
    Fidel Jr PL, Vasquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev. 1999;12:80–96.PubMedCentralPubMedGoogle Scholar
  40. 40.
    Ibara AS, Marcorelles P, Le Martelot MT, Touffet N, Moalic E, Hery-Arnaud G, et al. Two cases of systemic Candida glabrata infection following in vitro fertilization and embryo transfer. Eur J Clin Microbiol Infect Dis. 2004;23:53–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Khan ZU, Ahmad S, Al-Obaid I, Al-Sweih NA, Joseph L, Farhat D. Emergence of resistance to amphotericin B and triazoles in Candida glabrata vaginal isolates in a case of recurrent vaginitis. J Chemother. 2008;20:488–91.CrossRefPubMedGoogle Scholar
  42. 42.
    Ozer E, Unlu M, Ersen A, Gulekli B. Intrauterine fetal loss associated with Candida glabrata chorioamnionitis: report of two cases. Turk Patoloji Derg. 2013;29:77–9.PubMedGoogle Scholar
  43. 43.
    Darmstadt GL, Dinulos JG, Miller Z. Congenital cutaneous candidiasis: clinical presentation, pathogenesis, and management guidelines. Pediatrics. 2000;105(2):438.CrossRefPubMedGoogle Scholar
  44. 44.
    Almeida Santos L, Beceiro J, Hernandez R, Salas S, Escriba R, Garcia Frias E, et al. Congenital cutaneous candidiasis: report of four cases and review of the literature. Eur J Pediatr. 1991;150(5):336.CrossRefPubMedGoogle Scholar
  45. 45.
    Workowski KA, Berman S. Centers for Disease Control and Prevention (CDC) sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1.PubMedGoogle Scholar
  46. 46.
    Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database Syst Rev. 2001.Google Scholar
  47. 47.
    United Kingdom National Guideline on the Management of Vulvovaginal Candidiasis (2007). Available at www.bashh.org/documents/1798. (Accessed 4 Dec 2008).
  48. 48.
    Young G, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database of Systematic Reviews 2001. Issue 4.Google Scholar
  49. 49.
    Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol. 2005;73(11):919.CrossRefPubMedGoogle Scholar
  50. 50.
    FDA Drug Safety Communication: use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants http://www.fda.gov/Drugs/DrugSafety/ucm266030.htm.
  51. 51.
    Mølgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med. 2013;369(9):830.CrossRefPubMedGoogle Scholar
  52. 52.
    Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy. 1999;19(2):221.CrossRefPubMedGoogle Scholar
  53. 53.
    Sorensen HT, Nielsen GL, Olesen C, Larsen H, Steffensen FH, Schønheyder HC, et al. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol. 1999;48(2):234.CrossRefPubMedCentralPubMedGoogle Scholar
  54. 54.
    Inman W, Pearce G, Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy. Eur J Clin Pharmacol. 1994;46(2):115–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Mastroiacovo P, Mazzone T, Botto LD, Serafini MA, Finardi A, Caramelli L, et al. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol. 1996;175(6):1645.CrossRefPubMedGoogle Scholar
  56. 56.
    Nørgaard M, Pedersen L, Gislum M, Erichsen R, Søgaard KK, Schønheyder HC, et al. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. J Antimicrob Chemother. 2008;62(1):172.CrossRefPubMedGoogle Scholar
  57. 57.
    Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol. 1998;105(8):882–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351(9):876.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyWayne State University School of MedicineDetroitUSA
  2. 2.Department of Internal Medicine, Division Infectious DiseasesWayne State University School of MedicineDetroitUSA
  3. 3.Harper HospitalDetroitUSA

Personalised recommendations